Bioequivalence tests to be stimulated

The Korea Food and Drug Administration says that in-house undertakings of bioequivalence tests by pharmaceutical firms will be stimulated by the policy of the administration to conduct its commissioned standard bioequivalence protocol study for the following 15 ingredients in addition to the current 96:

- Oxolamine citrate, deflazacort, mequitazine, mirtazapine, ceftibuten, naltrexone HCl, c...